How Scientists Made a Peptide Drug You Can Swallow: The Story of Oral Semaglutide
Oral semaglutide overcame the challenge of delivering a peptide drug as a pill through an innovative absorption enhancer, achieving comparable blood sugar and weight benefits to the injectable form.
Quick Facts
What This Study Found
The clinical development of oral semaglutide progressed through key phases:
- Phase 1: Demonstrated dose-dependent HbA1c and body weight reductions; characterized pharmacokinetics and drug interactions with food, disease states, and concomitant medications; established optimal dosing conditions (fasting, minimal water, 30-minute wait before eating)
- Phase 2: Confirmed significant HbA1c and weight reductions comparable to subcutaneous semaglutide, guiding dose selection (3 mg, 7 mg, 14 mg)
- Phase 3 (PIONEER program): Demonstrated significant HbA1c reduction, weight loss, and cardiovascular safety
- The absorption enhancer SNAC (sodium N-[8-(2-hydroxybenzoyl)amino]caprylate) was key to enabling gastric absorption and peptide stability
- Oral semaglutide (Rybelsus) became the first approved oral GLP-1 RA for T2DM
Key Numbers
How They Did This
Comprehensive review of the clinical development program for oral semaglutide, covering Phase 1 (PK/PD, safety, dose-response), Phase 2 (dose-finding), and Phase 3 (PIONEER program) trials. Focuses on the pharmacological innovations that enabled oral peptide delivery.
Why This Research Matters
Making a peptide drug into a pill was considered nearly impossible for decades. Oral semaglutide's success opens the door for other oral peptide therapies — potentially transforming how patients take medications that currently require injections. Patient adherence improves dramatically when switching from injections to pills.
The Bigger Picture
Oral semaglutide represents a pharmaceutical milestone — proving that peptide drugs can be effectively delivered orally. This technology platform (SNAC-based absorption enhancement) could be applied to other peptide drugs currently requiring injection, potentially revolutionizing how we deliver biologics and expanding patient access to peptide-based therapies.
What This Study Doesn't Tell Us
Oral semaglutide has lower bioavailability than the injectable form, requiring specific dosing conditions (fasting, limited water, 30-minute wait) that may reduce convenience. The SNAC technology works primarily through gastric absorption, which may not be applicable to all peptide drugs. Higher doses are needed orally to achieve comparable effects to injection.
Questions This Raises
- ?Can the SNAC technology be applied to make other injectable peptide drugs available as pills?
- ?Will next-generation oral peptide formulations eliminate the strict dosing conditions?
- ?How does long-term adherence with oral semaglutide compare to injectable forms in real-world use?
Trust & Context
- Key Stat:
- First oral GLP-1 RA Oral semaglutide (Rybelsus) broke the barrier of oral peptide delivery, achieving HbA1c and weight reductions comparable to injectable semaglutide
- Evidence Grade:
- This review synthesizes data from multiple completed clinical trial phases (1, 2, and 3), including the pivotal PIONEER program that supported FDA approval. The underlying evidence is strong and well-established.
- Study Age:
- Published in 2025, this review provides a comprehensive retrospective of oral semaglutide's clinical development, useful for understanding both the drug and the oral peptide delivery technology.
- Original Title:
- Clinical development of oral semaglutide for the treatment of type 2 diabetes mellitus: focusing on early phase clinical trials.
- Published In:
- Translational and clinical pharmacology, 33(1), 1-9 (2025)
- Authors:
- Won, Heejae, Cho, Joo-Youn, Lee, SeungHwan
- Database ID:
- RPEP-14170
Evidence Hierarchy
Frequently Asked Questions
Why is it so hard to make a peptide drug into a pill?
Peptides are small proteins that get destroyed by stomach acid and digestive enzymes, and they're too large to easily cross the gut wall into the bloodstream. Oral semaglutide overcomes these barriers with SNAC — a special molecule that temporarily protects the peptide and opens a pathway for absorption through the stomach lining.
Is the oral semaglutide pill as effective as the injection?
Clinical trials showed comparable HbA1c and weight reductions between oral and injectable semaglutide, though the oral form requires higher doses to achieve similar blood levels. The main trade-off is that the pill must be taken fasting with very little water and you must wait 30 minutes before eating — specific conditions needed for proper absorption.
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-14170APA
Won, Heejae; Cho, Joo-Youn; Lee, SeungHwan. (2025). Clinical development of oral semaglutide for the treatment of type 2 diabetes mellitus: focusing on early phase clinical trials.. Translational and clinical pharmacology, 33(1), 1-9. https://doi.org/10.12793/tcp.2025.33.e3
MLA
Won, Heejae, et al. "Clinical development of oral semaglutide for the treatment of type 2 diabetes mellitus: focusing on early phase clinical trials.." Translational and clinical pharmacology, 2025. https://doi.org/10.12793/tcp.2025.33.e3
RethinkPeptides
RethinkPeptides Research Database. "Clinical development of oral semaglutide for the treatment o..." RPEP-14170. Retrieved from https://rethinkpeptides.com/research/won-2025-clinical-development-of-oral
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.